The Pre-Clinical Genome Editing facility provides a centralised hub for the innovation, application and use of state-of-the-art genome editing technologies in vitro and in vivo.
We have extensive expertise in the design and implementation of Genome Editing approaches across a range of cell types, in vitro and in vivo to enable researchers to address their biological questions.
- Delivery systems: non-viral (microinjection, electroporation, lipofection, etc), viral (AAV, Lenti, Adenovirus)
- Editing technologies: CRISPRn (Knock-Out, Knock-In), dCas9-based technologies, non-SpCas9 technologies
- Cell types: primary human and mouse (incl. mESC, mouse Zygotes), mouse and human cell lines (normal and cancer)
We are also experts in the design and generation of novel mouse lines for cancer research.
Finally, we specialise in the design and implementation of Pre-Clinical studies using two in vivo cancer models: a model of pancreatic cancer (KPC) and patient-derived xenografts of human breast tumours (PDX).
Please visit our website for more detail on who we are, what we are currently up to, for job opportunities, and for means to get in touch with us: